TY  - CHAP
M1  - Book, Section
TI  - Management of Malignant Pleural Effusions
A1  - Sesti, Joanna
A1  - Paul, Subroto
A1  - Zellos, Lambros
A1  - Bizekis, Costas S.
A1  - Zervos, Michael D.
A1  - Pass, Harvey I.
A2  - Sugarbaker, David J.
A2  - Bueno, Raphael
A2  - Burt, Bryan M.
A2  - Groth, Shawn S.
A2  - Loor, Gabriel
A2  - Wolf, Andrea S.
A2  - Williams, Marcia
A2  - Adams, Ann
Y1  - 2020
N1  - 
T2  - Sugarbaker’s Adult Chest Surgery, 3e
AB  - Malignant  pleural  effusions  (MPEs)  cause  considerable  morbidity  for  patients  afflicted  with  cancer.  Metastatic  breast,  lung,  and  ovarian  cancers  account  for  the  majority  of  cases.  Although  there  have  been  no  epidemiologic  studies,  the  annual  incidence  of  MPEs  in  the  United  States  is  estimated  to  be  more  than  200,000  cases.1,2  Initial  malignant  diagnosis  can  be  established  in  50%  to  60%  of  patients  by  means  of  a  therapeutic  thoracentesis.2,3  However,  the  malignant  effusions  often  recur,  and  patients  require  long-term  palliation.  The  ideal  therapy  permits  expedient,  low-cost  management  of  the  pleural  effusion  with  minimal  morbidity  because  many  of  these  patients  have  terminal  disease.  Nonoperative  management  of  MPEs  includes  systemic  chemotherapy  and  radiation  therapy,  as  well  as  several  methods  of  mechanical  drainage.  Operative  management  includes  drainage  through  the  use  of  video-assisted  thoracic  surgery  (VATS)  techniques  combined  with  pleurodesis,  as  well  as  operative  placement  of  indwelling  drainage  catheters  and  pleuroperitoneal  shunts.3–5  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accesssurgery.mhmedical.com/content.aspx?aid=1170414204
ER  -